MASH and MASLD are prevalent, complex diseases often accompanied by metabolic comorbidities like obesity and diabetes. GLP-1 receptor agonists, such as semaglutide, show promise in resolving NASH ...

It means that the committee can now accept evidence generated by the tool as scientifically valid in future applications and assessments for new MASH treatments. MASH is a condition linked with ...

Souza M, Al-Sharif L, Diaz I, et al. Representation of sex, race and ethnicity in mash randomised controlled trials: a systematic review and meta-analysis. Liver Int . 2025;45(4):e70029. doi:10. ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...